Pillstats
Rx only · Suspension, Extended Release · Oral

Hydrocodone Polistirex And Chlorpheniramine Polistirex

Chlorpheniramine Maleate + Hydrocodone Bitartrate

2 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US4 NDCs
2 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
RxCUI (US)2400
US makers2 labelers
Packages6
DEA / ScheduleCII

US acquisition costNADAC · per unit

Average across 2 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$0.167$0.334$0.502$0.669Dec 2025Apr 2026Jul 2026
$0.579
Latest avg · Jul 22, 2026
+23%
Since Dec 17, 2025
2
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

4869721.5K1.9K2025 Q12025 Q22025 Q32025 Q42026 Q1
691
Rx · 2026 Q1
65K
Units dispensed
-59%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it2 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Bryant Ranch Prepackrepackager4SUPPLYING
Cranbury Pharmaceuticals, LLCunknown2SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Jul 11, 2019
    RECALLRecall (Class II): Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Suspension, (equivalent to 10 mg hydrocodone bi…

    Superpotent Drug and Failed Stability Specifications: High out-of-specification results for the active ingredients, hydrocodone and chlorpheniramine, as well as high out-of-specification results for the preservatives. — Recalling firm: Tris Pharma Inc. — Nationwide in the USA and Puerto Rico